• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom
ConclusionsThe absolute risk of simvastatin-related myopathy is low, but individuals at higher risk can be identified to help guide patient management. The lack of association of the myopathy risk score with other muscle symptoms reinforces randomized placebo-controlled evidence that statins do not cause the vast majority of reported muscle symptoms.
Source: European Heart Journal - July 23, 2020 Category: Cardiology Source Type: research

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
Conclusion The risk of myopathy was increased by adding ERN/LRPT to simvastatin 40 mg daily (with or without ezetimibe), particularly in Chinese patients whose myopathy rates on simvastatin were higher. Despite the side effects of ERN/LRPT, among individuals who were able to tolerate it for ~1 month, three-quarters continued to take it for ~4 years.
Source: European Heart Journal - May 1, 2013 Category: Cardiology Authors: HPS2-THRIVE Collaborative Group, Haynes, Jiang, Hopewell, Li, Chen, Parish, Landray, Collins, Armitage, Collins, Armitage, Baigent, Chen, Landray, Chen, Jiang, Pedersen, Landray, Bowman, Chen, Hill, Haynes, Knott, Rahimi, Tobert, Sleight, Simpson, Parish, Tags: FASTTRACK CLINICAL Source Type: research

Niacin Adverse Events in HPS2-THRIVENiacin Adverse Events in HPS2-THRIVE
Extended-release niacin and laropiprant added to simvastatin were associated with a significantly increased risk of definite myopathy. Interestingly, the risk of myopathy was significantly higher in randomized patients from China than in patients from Europe. Heartwire
Source: Medscape Today Headlines - February 27, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

HPS2-THRIVE: High myopathy risk with niacin/laropiprant
Extended-release niacin and laropiprant added to simvastatin were associated with a significantly increased risk of definite myopathy. Interestingly, the risk of myopathy was significantly higher in randomized patients from China than in patients from Europe.
Source: theHeart.org - February 27, 2013 Category: Cardiology Source Type: news

MHRA Drug Safety Update: TredaptiveT (niacin-laropiprant) no longer recommended for prescribing
Source: MHRA Area: News The January issue of the MHRA's Drug Safety Update has featured new data from a long-term study (HPS2-THRIVE) involving over 25 000 patients which indicated that adding TredaptiveT (fixed dose niacin-laropiprant) to simvastatin did not provide significant additional benefit in reducing the risk of major vascular events compared with statin therapy alone. In addition, a higher frequency of bleeding (intracranial and gastro-intestinal), myopathy, infections and new-onset diabetes was seen in patients taking Tredaptive with simvastatin, compared with patients taking simvastatin alone.   In li...
Source: NeLM - Cardiovascular Medicine - January 30, 2013 Category: Cardiology Source Type: news